dual glp-1/gip agonist The action of tirzepatide on various organs. GLP-1: GLP-1/GIP Dual Receptor Agonist -

Retatrutide administered once weekly subcutaneously for 12 weeks resulted in a dose-dependent placebo-adjusted weight loss of up to 8.96 kg in the highest dose group and a placebo-adjusted HbA1c reduction of up to 1.6% in a phase II trial in individuals with T2DM [125]

So that's the weight loss meets hormone therapy component that I think is important to consider when women are in menopause

Q.LiL.et al (2022)

If you need to lose weight for your health, Ozempic is more effective

ACE/ARB, angiotensin converting enzyme inhibitors/angiotensin-receptor blockers Postop, Postprocedural

Discussion This study systematically quantitatively assessed the efficacy and safety characteristics of 12 marketed and experimental GLP-1RA drugs